- Cross-border Ebola epidemic expands across DRC, Kenya, and Uganda
- Doctors without Borders and the WHO addressed the Ebola outbreak in the DRC, declaring it a public health emergency.
- WHO representatives provide updates on the current Ebola outbreak in the DRC, while researchers study potential interventions.
Regeneron secures $270M contract extension for Ebola therapy supply
What happened
Regeneron Pharmaceuticals agreed to a contract extension worth nearly $270 million to supply its Ebola therapy, Inmazeb, to the US Government through 2031. This agreement builds on a 2020 partnership with the Biomedical Advanced Research and Development Authority. Separately, an investigational monotherapy derived from the therapy is being tested in the Democratic Republic of the Congo against a Bundibugyo virus outbreak.
Why it matters
The contract extension ensures a ready supply of Inmazeb for national emergency stockpiles, reinforcing preparedness efforts. Additionally, the ongoing clinical trials are evaluating a candidate treatment for a virus outbreak in the Democratic Republic of the Congo for which no approved treatments are currently available.
The World Health Organization and Doctors Without Borders have addressed the Ebola outbreak in the Democratic Republic of the Congo, declaring it a public health emergency.
Who's involved
- Regeneron PharmaceuticalsPharmaceutical company supplying the Ebola therapy, Inmazeb
- Biomedical Advanced Research and Development AuthorityGovernment organization that secured the contract extension for national stockpiles
- FDARegulatory agency that oversees Regeneron Pharmaceuticals' drug development
- Democratic Republic of the CongoCountry where the Bundibugyo virus outbreak is currently being studied
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Regeneron PharmaceuticalsSpeculative
Regeneron Pharmaceuticals could see increased revenue from the extended government supply contract.
The Biomedical Advanced Research and Development Authority could reinforce its national preparedness mandate through the secured supply.
Keep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
-
Democratic Republic of the Congo
country in Central Africa
- FDA